Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to food intake, stimulating insulin production and suppressing glucagon secretion. GLP-1 derivatives exhibit promising therapeutic results in treating type